Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Swedish Orphan Biovitrum to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, profitability, valuation and earnings.
Profitability
This table compares Swedish Orphan Biovitrum and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Swedish Orphan Biovitrum | 20.67% | 17.92% | 9.30% |
| Swedish Orphan Biovitrum Competitors | -12,224.75% | -204.85% | -31.52% |
Volatility & Risk
Swedish Orphan Biovitrum has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum’s rivals have a beta of -1.85, meaning that their average share price is 285% less volatile than the S&P 500.
Institutional and Insider Ownership
47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations and price targets for Swedish Orphan Biovitrum and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Swedish Orphan Biovitrum | 0 | 3 | 5 | 0 | 2.62 |
| Swedish Orphan Biovitrum Competitors | 9926 | 15343 | 45765 | 1601 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 114.68%. Given Swedish Orphan Biovitrum’s rivals higher possible upside, analysts clearly believe Swedish Orphan Biovitrum has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares Swedish Orphan Biovitrum and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Swedish Orphan Biovitrum | $2.89 billion | $48.85 million | 25.40 |
| Swedish Orphan Biovitrum Competitors | $688.58 million | $7.69 million | -17.98 |
Swedish Orphan Biovitrum has higher revenue and earnings than its rivals. Swedish Orphan Biovitrum is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Swedish Orphan Biovitrum beats its rivals on 8 of the 13 factors compared.
Swedish Orphan Biovitrum Company Profile
Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.
Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.
